By John Carroll Third Rock Ventures and Prospect Venture Partners have partnered on a $33 million Series A for NinePoint Medical, a Cambridge, MA-based startup that is developing new technology that can be used to examine gastrointestinal tissue for precancerous and cancerous cells. NinePoint’s goal is to give gastroenterologists a real-time diagnostic tool that would …
By John Carroll Designing a better antibody is one of the hottest strategies driving start-up biotechs in the U.S. And one recent entry in the field has picked up a pair of powerhouse venture backers. This morning CytomX Therapeutics announced that it banked $30 million from a Series B led by Third Rock Ventures and …
By John Carroll Boston-based Third Rock Ventures, one of the busiest and best connected biotech investors in the business, has raised $426 million for its second fund and has officially announced plans for a West Coast office. Former Portola CEO Charles Homcy will take over as the partner in charge of the San Francisco office and Alexis Borisy, who …
By John Carroll Third Rock is jumping on board the venture bandwagon backing the Boston-based start-up Rhythm, pushing its Series A to $40 million to fuel new trial work on peptide therapeutics. MPM Capital and New Enterprise put together the initial $21 million venture round for Rhythm in the spring. Bart Henderson, president of Rhythm, …
